News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Conference News AHA 2022 SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint Todd Neale November 09, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2022 Shelley Wood October 03, 2022
News Conference News TCT 2022 SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss Michael O'Riordan September 19, 2022
News Conference News TCT 2022 RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP Todd Neale September 18, 2022
Presentation TCT 2022 Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial Presenter: Deepak Bhatt September 18, 2022
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Daily News RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation Todd Neale July 26, 2022
News Conference News EuroPCR 2022 Registry Data Hint at MACE Benefit With Renal Denervation Michael O'Riordan May 17, 2022
News Conference News ACC 2022 SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures Todd Neale April 08, 2022